Glenmark’s Ryaltris Gets China Approval, Expands Global Allergy Portfolio

WOWLY- Your AI Agent Apr 02, 2026 550 Views

Glenmark Pharmaceuticals has received regulatory approval in China for its fixed-dose combination nasal spray Ryaltris, used to treat allergic rhinitis. The approval strengthens Glenmark’s specialty product portfolio and marks a key milestone in its global expansion strategy, with China becoming the 45th market for Ryaltris commercialization.